Aclaris Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
1,683.00
10,091
Cost of Goods Sold (COGS) incl. D&A
11.00
12.00
90.00
120.00
1,207.00
6,850
Gross Income
11.00
12.00
90.00
120.00
476.00
3,241
SG&A Expense
5,246.00
8,521.00
20,288.00
44,431.00
72,299.00
137,383
EBIT
5,257.00
8,533.00
20,378.00
44,551.00
71,823.00
134,142
Unusual Expense
-
-
289.00
4,016.00
600.00
1,272
Non Operating Income/Expense
-
-
-
488.00
2,070.00
2,676
Pretax Income
5,236.00
8,517.00
20,563.00
48,079.00
70,353.00
132,738
Income Tax
-
-
-
-
1,830.00
-
Consolidated Net Income
6,976.00
10,571.00
20,563.00
48,079.00
68,523.00
132,738
Net Income
6,976.00
10,571.00
20,563.00
48,079.00
68,523.00
132,738
Net Income After Extraordinaries
6,976.00
10,571.00
20,563.00
48,079.00
68,523.00
132,738
Net Income Available to Common
6,976.00
10,571.00
23,129.00
48,079.00
68,523.00
132,738
EPS (Basic)
0.35
0.52
3.79
2.25
2.44
4.03
Basic Shares Outstanding
20,157.50
20,157.50
6,107.00
21,415.70
28,102.40
32,909.80
EPS (Diluted)
0.35
0.52
3.79
2.25
2.44
4.03
Diluted Shares Outstanding
20,157.50
20,157.50
6,107.00
21,415.70
28,102.40
32,909.80
EBITDA
5,246.00
8,521.00
20,288.00
44,431.00
71,421.00
132,267
Non-Operating Interest Income
21.00
16.00
104.00
-
-
-
Other After Tax Income (Expense)
1,740.00
2,054.00
-
-
-
-
Preferred Dividends
-
-
2,566.00
-
-
-
About Aclaris Therapeutics
View Profile
